Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, shares her thoughts on the current treatment landscape for chronic graft-versus-host disease (cGvHD), highlighting unmet needs. Although there are now three approved drugs for cGvHD, it is necessary to conduct further studies comparing these drugs or investigating drug combinations to determine the best treatment algorithm for each individual patient. In addition, Dr Pusic talks on the importance of testing drugs in the newly diagnosed setting without using high doses of steroids, as well as on finding biomarkers for cGvHD. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

свернуть